HOT :  Venetian Gondola Boat , Macau Tower , Galaxy 3 In 1 Package

SINGAPORE, Feb. 26, 2018 /PRNewswire/ -- Revamped and revitalised from BioPharma Asia, Phar-East 2018, organised by Terrapinn, will bring over 120 expert speakers sharing on the latest trends and developments on 9 conference tracks: Market Access, Vaccines, Cell & Therapy, Biotech Innovation, Regulatory Affairs and brand new for 2018: Pharma Partnering & Licensing, Immunotherapy, Pharma 4.0, Biosimilars,

Held from 1 - 2 March in Suntec Convention Centre, Singapore, the conference will bring over 120 expert speakers. Here's a sample of them:

  • Forrest Hu, General Manager, International Business, 3SBio, China
  • Uday Saxena, President & CEO, Reddy US Therapeutics, Former CSO, Dr Reddy's Laboratories, Co-founder & Chief Advisor R&D, Kareus
  • Yuliana Indriati, President Director, PT Kalbe Genexine Biologics, Indonesia
  • Mike Zhang, CEO, Liaoning Chengda Biotechnology, China
  • Victor Li, CEO, LionTCR, Singapore
  • Hardy Chan, Chairman & President, Allianz Pharmascience, Taiwan
  • Antonio Lee, CEO & Managing Director, MEDIPOST America, Global Head, Business Development, MEDIPOST, South Korea
  • Mrunalini Jagtap, Data Management Lead, Singapore Institute for Clinical Sciences (SICS), A*STAR, Singapore

See full speakers list here: www.terrapinn.com/exhibition/phar-east/speakers.stm

Opening keynotes on Day 1, 1st March includes:

  • Venture capital funding for the biotech industry
    Carolyn Ng, Vice President, Vertex Ventures, a member of Temasek Holdings, Singapore
  • Fostering biotech and bio-entrepreneurship in Southeast Asia (SEA): How do we build the next biotech unicorn in SEA?
    John Connolly, Chief Scientific Officer, Tessa Therapeutics, Singapore
  • Panel- The Macro View: What will it take for Asia's biotech industry to really flourish?
    • Joe Zhou, CEO, Genor Biopharma, China
    • Uday Saxena, President & CEO, Reddy US Therapeutics, Former CSO, Dr Reddy's Laboratories, India
    • Jerome Cabannes, COO, AJ Biologics, Malaysia
    • Mike Zhang, CEO, Liaoning Chengda Biotechnology, China
    • Antonio Lee, CEO & Managing Director, MEDIPOST America, Global Head, Business Development, MEDIPOST, South Korea

120 other pharma leaders are confirmed to speak at Phar-East 2018 across 9 tracks - view more details at: http://www.terrapinn.com/exhibition/phar-east/speakers.stm

In addition to the main conference, a pre-conference day will be held on 28th February featuring the following workshops:

  1. Biotech Bootcamp Workshop -- Sponsored by JTC
  2. Workshop on Claim Drafting -- Making your PCT claims fit for a fast grant at the EPO -- Sponsored by European Patent Office (EPO)
  3. Workshop on the topic of: "Harness the power of data for smarter drug development" -- Sponsored by Medidata
  4. Regulatory Affairs Workshop -- Jack Wong, Head of Regulatory Affairs, Baxter, Singapore in collaboration with ARPA

Find out more at: http://www.terrapinn.com/exhibition/phar-east/index.stm

About Phar-East 2018

Dates
Conference: 1 - 2 March 2018
Pre-conference day: 28th February 2018

Conference opening hours: 08:45 am
Venue: Level 3, Summit 2 (entrance from Summit 1), Suntec Singapore International Convention & Exhibition Centre
Website:  http://www.terrapinn.com/exhibition/phar-east/index.stm

About Terrapinn
Terrapinn is a business media company. Its products are trade exhibitions, conferences, training solutions and electronic and print publications. For more information, please visit www.terrapinn.com.

Note: Press registration for the conference is compulsory and advance scheduling for speaker/ sponsor interviews is recommended. Final issuance of press passes is subjected to Terrapinn's discretion. 

SALE :  SKY100  ,   Madame Tussauds  ,  HK 3D Museun ;

News Sources
About PR Newswire
PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, public relations officers and investor relations professionals to engage with their key audiences: businesses and consumers, the media, and investors.